Suchergebnisse - "Pierga, Jean-Yves"

PubPharm (55)

1

Fulvestrant and everolimus efficacy after CDK4/6 inhibitor : a prospective study with circulating tumor DNA analysis

enthalten in: Oncogene | 2024

von Vasseur, A. | Cabel, L. | Hego, C. | +12

2

Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer

enthalten in: JAMA network open | 2024

von Frenel, J. | Zeghondy, J. | Guérin-Charbonnel, C. | +18

3

Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns

enthalten in: JAMA network open | 2023

von Gougis, P. | Grandal, B. | Jochum, F. | +14

4

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1) : a randomised, open-label, multicentre, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Bidard, F. | Hardy-Bessard, A. | Dalenc, F. | +115

CommentIn: Nat Rev Clin Oncol. 2023 Feb;20(2):67-68. - PMID 36424404

5

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

enthalten in: The New England journal of medicine | 2022

von Modi, S. | Jacot, W. | Yamashita, T. | +136

CommentIn: Nat Rev Clin Oncol. 2022 Aug;19(8):493. - PMID 35778612

6

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

enthalten in: The New England journal of medicine | 2022

von Cortés, J. | Kim, S. | Chung, W. | +122

CommentIn: Nat Rev Clin Oncol. 2022 May;19(5):283. - PMID 35361895

7

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

enthalten in: The New England journal of medicine | 2021

von Kalinsky, K. | Barlow, W. | Gralow, J. | +31

CommentIn: Nat Rev Clin Oncol. 2022 Feb;19(2):72. - PMID 34912052

8

Disseminated tumour cells from the bone marrow of early breast cancer patients : Results from an international pooled analysis

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Hartkopf, A. | Brucker, S. | Taran, F. | +34

9

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa) : a randomised, open-label, multicentre, non-inferiority, phase 3 study

enthalten in: The Lancet. Oncology | 2021

von Tan, A. | Im, S. | Mattar, A. | +15

CommentIn: Lancet Oncol. 2021 Jan;22(1):5-6. - PMID 33357419

10

Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer : The STIC CTC Randomized Clinical Trial

enthalten in: JAMA oncology | 2021

von Bidard, F. | Jacot, W. | Kiavue, N. | +22

CommentIn: JAMA Oncol. 2021 Jan 1;7(1):30-31. - PMID 33151269

1
2
3
4
5
6
Nächster »
[6]